Safety of Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: Interim Results From an Open-Label, Non-Inferiority, Randomized Controlled Trial

In vitro activity of omadacycline and comparator agents against a collection of Neisseria gonorrhoeae urine isolates collected from the United States during 2018-2020

Current Prescribing Practices and Guideline Concordance for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) among Outpatient and Urgent Care Visits

Surveillance of omadacycline in vitro activity against 35,000 bacterial clinical isolates from the United States (2019–2023)

Evaluation of Fecal Pharmacokinetics and Metagenomic Changes Following the Administration of Intravenous Omadacycline to Healthy Subjects

Clinical and microbiological outcomes of omadacycline for pulmonary Mycobacterium abscessus complex

Pharmacokinetics of omadacycline in adults with cystic fibrosis

Omadacycline is Active Against Multidrug Resistant Bacillus Anthracis Strains Resistant to Tetracyclines

Evaluation of Omadacycline Treatment for Osteomyelitis

In Vitro Interaction of Omadacycline in Combination with Melatonin against Carbapenemase producing Klebsiella pneumoniae

Omadacycline as Salvage Therapy for Pulmonary Mycobacterium Abscessus Complex

Minimum inhibitory concentrations (MICs) of tigecycline correlate strongly with those of omadacycline

Omadacycline alone and in combination as a treatment option for Mycobacterium avium infections

Immunomodulatory activity of omadacycline in vitro and in a murine model of acute lung injury (ALI)

Real-World Outpatient Use of Omadacycline for Bone and Joint Infections

Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022)

Early Experience With Omadacycline For The Treatment Of Diabetic Foot Infections

A Functional OMICS Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects

Omadacycline for the Treatment of Non-Pulmonary Mycobacterial Infections: a Single-Center Retrospective Review

Omadacycline is Efficacious in a Treatment Model of Inhalational Anthrax in New Zealand White Rabbits

In vitro activity of omadacycline and comparator agents against 485 infrequently encountered bacterial pathogens from the SENTRY surveillance programmme

Gut microbiome diversity and bacterial taxonomic group changes in healthy volunteers receiving oral omadacycline or vancomycin

Quantifying antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacteria infections: an opportunity for novel agents?

Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021)

A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections

Bile Acid Concentrations in Healthy Volunteers Receiving Oral Omadacycline or Vancomycin

Preclinical evaluation of omadacycline for potential as a drug to treat Acinetobacter baumannii and Klebsiella pneumoniae infections in combat wounds

In Vitro Activity of Omadacycline against Chlamydia trachomatis Serovars

Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of omadacycline in adults with Mycobacterium abscessus complex (MABc) pulmonary disease

Clinical Response to Intravenous versus Oral Treatment in Patients with Acute Bacterial Skin and Skin Structure Infections

Omadacycline is not a Substrate for Clinically Relevant Beta-Lactamase Enzymes

Omadacycline in Female Adults with Cystitis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study

Omadacycline in Female Adults with Acute Pyelonephritis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study

Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients

Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients

Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and GramNegative Bacteria

No items found.

No items found.

No items found.

2020

Conference Presentations

IDWEEK

accordio_arrow

Contact Us

If you would like to speak to a Paratek Medical Information Professional please call 1-833-PARATEK (1-833-727-2835) or email medinfo@paratekpharma.com. Otherwise please see below.

Medical Information

If you would like to speak to a Paratek Medical Information Professional please call Paratek Customer Service at 1-833-PARATEK (1-833-727-2835) (Monday to Friday, 8 AM to 8 PM ET, excluding holidays) or email medinfo@paratekpharma.com

Submit an Inquiry

Report a Product Complaint

To report a Product Quality Complaint for a Paratek product, please call 1-833-Paratek (1-833-727-2835).

Report an Adverse Event

To report an Adverse Event for a Paratek product, please fill out a form or call us 1-833-PARATEK (1-833-727-2835). You can also contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Submit an Adverse Event Report

Request follow-up from a Medical Science Director

If you would like additional information about our products or would like to discuss research ideas, please contact our MSD team.